Hansoh Pharmaceutical Group Company Limited Share Price

Equities

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. 09:08:24 20/06/2025 BST 5-day change 1st Jan Change
28.00 HKD +0.90% Intraday chart for Hansoh Pharmaceutical Group Company Limited -4.76% +62.04%

Valuation: Hansoh Pharmaceutical Group Company Limited

Capitalization 152B 166B 21.21B 18.4B 17.33B 15.74B 29.13B 1,837B 32.82B 205B 78.53B 841B 79.58B 77.89B 3,093B P/E ratio 2025 *
32.6x
P/E ratio 2026 * 31.1x
Enterprise value 127B 139B 17.65B 15.31B 14.42B 13.1B 24.24B 1,529B 27.31B 171B 65.36B 700B 66.23B 64.82B 2,574B EV / Sales 2025 *
9.28x
EV / Sales 2026 * 8.28x
Free-Float
18.75%
Yield 2025 *
1.03%
Yield 2026 * 1.06%
More valuation ratios * Estimated data
Dynamic Chart
Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for Marketing 06-04 CI
Hansoh Pharmaceutical Says Aumolertinib Mesilate Tablets Approved By MHRA For Marketing 06-04 RE
Hansoh Pharma's Lung Cancer Drug Aumseqa Wins UK Marketing Approval 06-04 MT
Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$25.64 From HK$19.86, Keeps at Neutral 06-03 MT
Hansoh Pharma Licenses GLP-1 Drug to Nasdaq-listed Regeneron in $2 Billion Deal 06-03 MT
Regeneron's weight-loss drug helps patients on Wegovy preserve muscle 06-02 RE
Hansoh Pharmaceutical Says Units Entered Into A License Agreement With Regeneron Pharmaceuticals 06-02 RE
Regeneron Signs Licensing Agreement for Chinese Weight Loss Drug 06-02 DJ
Hansoh Pharmaceutical Group Company Limited Announces the Third Biologics License Application of Xin Yue (Inebilizumab Injection) Has Been Accepted by the National Medical Products Administration 05-30 CI
Hansoh Pharmaceutical Says Third Biologics License Application Of Xinyue (Inebilizumab Injection) Accepted By NMPA 05-30 RE
Chinese Regulator Accepts Hansoh Pharmaceutical's License Application for Generalized Myasthenia Gravis Drug 05-30 MT
Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration 05-29 CI
Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration 05-29 CI
More news
1 day+0.90%
1 week-4.76%
Current month+8.32%
1 month+10.67%
3 months+39.30%
6 months+56.08%
Current year+62.04%
More quotes
1 week 26.8
Extreme 26.8
30.05
1 month 24.7
Extreme 24.7
30.85
Current year 15.96
Extreme 15.96
30.85
1 year 15.32
Extreme 15.32
30.85
3 years 9.41
Extreme 9.41
30.85
5 years 9.41
Extreme 9.41
46.7
10 years 9.41
Extreme 9.41
46.7
More quotes
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2015
Corporate Secretary 36 23/01/2025
Corporate Secretary 57 31/07/2018
Director TitleAgeSince
Chairman 64 01/12/2015
Director/Board Member 48 10/03/2016
Director/Board Member 38 01/12/2015
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.90%-4.76%+71.57%+96.35% 21.21B
-2.84%-6.91%-13.71%+156.52% 685B
-0.62%-4.65%+0.70%-13.42% 360B
-0.10%-3.02%+8.75%+29.16% 327B
-2.58%-7.83%-51.84%+25.00% 326B
-0.27%-3.86%+2.57%-13.95% 255B
-0.34%-2.34%+0.96%+20.36% 228B
-1.52%-5.41%-16.68%+2.61% 217B
-0.29%-3.24%-39.52%-10.19% 199B
-0.10%-2.00%-6.11%+21.36% 156B
Average -0.78%-4.23%-4.33%+31.38% 277.32B
Weighted average by Cap. -1.29%-4.71%-11.97%+45.08%
See all sector performances

Financials

2025 *2026 *
Net sales 13.65B 14.93B 1.9B 1.65B 1.55B 1.41B 2.61B 165B 2.94B 18.4B 7.04B 75.44B 7.13B 6.98B 277B 14.82B 16.21B 2.06B 1.79B 1.69B 1.53B 2.84B 179B 3.2B 19.98B 7.65B 81.92B 7.75B 7.58B 301B
Net income 4.61B 5.04B 642M 557M 524M 476M 881M 55.57B 993M 6.21B 2.38B 25.46B 2.41B 2.36B 93.58B 4.86B 5.31B 676M 587M 553M 502M 929M 58.58B 1.05B 6.54B 2.5B 26.84B 2.54B 2.48B 98.65B
Net Debt -25.54B -27.93B -3.56B -3.09B -2.91B -2.64B -4.89B -308B -5.51B -34.42B -13.17B -141B -13.35B -13.06B -519B -29.47B -32.23B -4.11B -3.56B -3.35B -3.05B -5.64B -356B -6.35B -39.72B -15.2B -163B -15.41B -15.08B -599B
More financial data * Estimated data
Logo Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.
Employees
8,989
More about the company
Date Price Change Volume
20/06/25 28.00 $ +0.90% 12,872,700
19/06/25 27.75 $ -1.42% 18,519,010
18/06/25 28.15 $ -0.53% 7,875,888
17/06/25 28.30 $ -3.41% 13,084,480
16/06/25 29.30 $ -0.34% 16,406,100

Delayed Quote Hong Kong S.E., June 20, 2025 at 09:08 am

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
25.61CNY
Average target price
26.83CNY
Spread / Average Target
+4.76%
Consensus

Quarterly revenue - Rate of surprise